By Editor , 29 October 2026

MADRID – October 28, 2026 -- Hengrui Pharma presented a record 64 oncology studies at the ESMO Congress 2026 in Madrid. Innovative oncology medicines generated 81.02% of the company's innovative medicine sales revenue in 2025.

By Editor , 29 October 2026

Melbourne – October 28, 2026 -- Envision Energy has unveiled an AI-powered hybrid energy system for mining and smelting that targets about 20% lower overall energy costs, a renewable electricity share above 80% and supply reliability exceeding 99.95%. The company presented the system at All Energy Australia. Results depend on local resources, system configuration and production requirements.

By Editor , 29 October 2026
A. O. Smith sells 81% of China unit to CPE in $400M deal

MILWAUKEE – October 28, 2026 -- A. O. Smith Corporation (NYSE: AOS) agreed to sell an 81% interest in its China business to alternative asset manager CPE, valuing the unit at approximately $400 million on a cash-free, debt-free basis. The company will keep a 19% stake and sign a long-term brand licensing agreement.

By Editor , 29 October 2026
Sands China Prices $1B Senior Notes to Refinance 2.300% Debt

LAS VEGAS – October 28, 2026 -- Sands China Ltd. has priced $1 billion of senior notes, with net proceeds of approximately $989 million earmarked largely to refinance existing debt, parent company Las Vegas Sands Corp. (NYSE: LVS) said.

Two-tranche offering carries coupons of 6.400% and 6.700%

The majority-owned LVS subsidiary priced $700 million of 6.400% senior notes due 2032 and $300 million of 6.700% senior notes due 2033. The offering is expected to close on November 3, 2026, subject to customary closing conditions.

By Editor , 29 October 2026
Lynk's Zemprocitinib Sustains 91.8% ACR20 Response Through Week 76

Hangzhou – October 28, 2026 -- Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib sustained a 91.8% ACR20 response rate at Week 76 in rheumatoid arthritis patients who had failed or could not tolerate biologic therapy, with no new safety signals in the pivotal Phase III trial.

By Editor , 29 October 2026

SHANGHAI – October 28, 2026 -- Lufax Holding Ltd (NYSE: LU, HKEX: 6623) reported a third-quarter 2026 net loss of RMB1,494 million (US$223 million), up from RMB380 million a year earlier, as credit impairment losses rose 10.3% and income tax expenses jumped 946.5%.

By Editor , 28 October 2026

SHANGHAI – October 27, 2026 -- Daqo New Energy Corp. (NYSE: DQ) cut its third-quarter 2026 net loss attributable to shareholders to $52.9 million from $81.2 million in Q2, as polysilicon sales volume tripled to 46,910 MT from 15,190 MT. Revenue rose to $194.2 million from $62.7 million in the prior quarter, though it remained below the $244.6 million booked in Q3 2025.

By Editor , 28 October 2026
3TREES Pitches Five Green Coating Lines at Big 5 Construct Kenya

PUTIAN – October 27, 2026 -- Chinese coatings maker 3TREES presented five green coating categories at Big 5 Construct Kenya, which opened on October 21, 2026, at the Sarit Expo Centre in Nairobi, as part of its push into East Africa.

3TREES covers wall and floor applications with five product lines at Hall 1, Booth 1J17

The portfolio included stone-effect exterior coatings, inorganic interior coatings, artistic finishes, waterproofing membranes and coatings, and floor coatings. The company markets the range under its "Create Healthy Life" philosophy.

By Editor , 27 October 2026
XCMG Climbs 10 Places to No. 202 on Fortune China 500

XUZHOU, China – October 27, 2026 -- XCMG Machinery (SHE: 000425) ranked No. 202 on the 2026 Fortune China 500, up 10 places from the previous year, and kept its lead among Chinese construction machinery companies.

The company attended the 2026 Fortune China 500 Summit in Chengdu on Oct. 22. Business leaders, entrepreneurs and scholars gathered there to discuss how companies can strengthen their competitiveness. The ranking itself was released in July.

By Editor , 27 October 2026
Single-Dose Cecolin 9 Interim Data Presented at IPVS 2026

Athens – October 27, 2026 -- Month 6 interim data comparing single-dose Cecolin 9 with Gardasil 9 were presented at the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), while final results from the Phase III SHINE I study are not expected until 2028.